BIOMAT Database Logo BIOMAT Database Logo

Laboratory aspirin resistance and the risk of major adverse cardiovascular events in patients with coronary heart disease on confirmed aspirin adherence. 2014

Jiabei Li, and Mingbao Song, and Zhao Jian, and Wenyun Guo, and Guozhu Chen, and Guoyan Jiang, and Juan Wang, and Xiaojing Wu, and Lan Huang
Institute of Cardiovascular Medicine, Xinqiao Hospital, Third Military Medical University.

OBJECTIVE Previous meta-analyses have demonstrated an increased risk of adverse events in aspirin-resistant patients. In this meta-analysis, we aimed to update clinical evidence regarding the relationship between aspirin resistance and major adverse cardiovascular events (MACEs) in patients with coronary heart disease (CHD) on confirmed aspirin adherence. METHODS An electronic literature search of PubMed, EMBASE, Web of Science and the Cochrane Library and a hand search of bibliographies through April 2013 were conducted. Studies were included if they prospectively investigated the association between aspirin resistance and the risk of adverse cardiovascular events during follow-up in CHD patients, mentioned confirmed compliance and provided adequate data for a statistical analysis. RESULTS Nine prospective studies with a total 1,889 CHD patients who were followed for one month to 2.5 years and study sample sizes ranging from 86 to 496 patients were identified. Overall, 622 of the 1,889 CHD patients (33.0%) were classified as being aspirin resistant with confirmed aspirin adherence. The aspirin-resistant patients exhibited a significantly higher risk of adverse events than the aspirin-sensitive patients (odds ratio 2.44, 95% confidence interval 1.81 to 3.30; p＜0.00001). CONCLUSIONS Among CHD patients, approximately one in three individuals can be diagnosed as aspirin resistant on confirmed aspirin adherence. Patients identified as having laboratory aspirin resistance exhibit a 2.4-fold increased risk of MACE compared with aspirin-sensitive patients.

UI MeSH Term Description Entries
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001241 Aspirin The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) Acetylsalicylic Acid,2-(Acetyloxy)benzoic Acid,Acetysal,Acylpyrin,Aloxiprimum,Colfarit,Dispril,Easprin,Ecotrin,Endosprin,Magnecyl,Micristin,Polopirin,Polopiryna,Solprin,Solupsan,Zorprin,Acid, Acetylsalicylic
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

Jiabei Li, and Mingbao Song, and Zhao Jian, and Wenyun Guo, and Guozhu Chen, and Guoyan Jiang, and Juan Wang, and Xiaojing Wu, and Lan Huang
Aspirin resistance and adverse clinical events in patients with coronary artery disease.
July 2007, The American journal of medicine,
Jiabei Li, and Mingbao Song, and Zhao Jian, and Wenyun Guo, and Guozhu Chen, and Guoyan Jiang, and Juan Wang, and Xiaojing Wu, and Lan Huang
Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events.
January 2009, Journal of postgraduate medicine,
Jiabei Li, and Mingbao Song, and Zhao Jian, and Wenyun Guo, and Guozhu Chen, and Guoyan Jiang, and Juan Wang, and Xiaojing Wu, and Lan Huang
Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease.
December 2016, Texas Heart Institute journal,
Jiabei Li, and Mingbao Song, and Zhao Jian, and Wenyun Guo, and Guozhu Chen, and Guoyan Jiang, and Juan Wang, and Xiaojing Wu, and Lan Huang
Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease.
July 2016, European heart journal,
Jiabei Li, and Mingbao Song, and Zhao Jian, and Wenyun Guo, and Guozhu Chen, and Guoyan Jiang, and Juan Wang, and Xiaojing Wu, and Lan Huang
Cardiovascular risk factors and the risk of major adverse limb events in patients with symptomatic cardiovascular disease.
November 2020, Heart (British Cardiac Society),
Jiabei Li, and Mingbao Song, and Zhao Jian, and Wenyun Guo, and Guozhu Chen, and Guoyan Jiang, and Juan Wang, and Xiaojing Wu, and Lan Huang
Impaired Peripheral Microvascular Function and Risk of Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease.
May 2021, Arteriosclerosis, thrombosis, and vascular biology,
Jiabei Li, and Mingbao Song, and Zhao Jian, and Wenyun Guo, and Guozhu Chen, and Guoyan Jiang, and Juan Wang, and Xiaojing Wu, and Lan Huang
Incidence and Cost of Major Adverse Cardiovascular Events and Major Adverse Limb Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease.
June 2019, The American journal of cardiology,
Jiabei Li, and Mingbao Song, and Zhao Jian, and Wenyun Guo, and Guozhu Chen, and Guoyan Jiang, and Juan Wang, and Xiaojing Wu, and Lan Huang
Prospective association of a genetic risk score with major adverse cardiovascular events in patients with coronary artery disease.
December 2017, Medicine,
Jiabei Li, and Mingbao Song, and Zhao Jian, and Wenyun Guo, and Guozhu Chen, and Guoyan Jiang, and Juan Wang, and Xiaojing Wu, and Lan Huang
Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease.
January 2018, Journal of internal medicine,
Jiabei Li, and Mingbao Song, and Zhao Jian, and Wenyun Guo, and Guozhu Chen, and Guoyan Jiang, and Juan Wang, and Xiaojing Wu, and Lan Huang
Risk prediction model for major adverse cardiovascular events (MACE) during hospitalization in patients with coronary heart disease based on myocardial energy metabolic substrate.
January 2023, Frontiers in cardiovascular medicine,
Copied contents to your clipboard!